TLDR Johnson & Johnson leads with a 3.0% yield and 62 consecutive years of dividend increases, trading at $206 with strong analyst support targeting $227 Coca-Cola offers a 2.9% yield with 63 years of dividend growth, backed by AI strategy and emerging market expansion with analysts targeting $82 Verizon provides the highest yield at 6.6% [...] The post Best Dividend Stocks for Long-Term Investors – December 2025 appeared first on CoinCentral.TLDR Johnson & Johnson leads with a 3.0% yield and 62 consecutive years of dividend increases, trading at $206 with strong analyst support targeting $227 Coca-Cola offers a 2.9% yield with 63 years of dividend growth, backed by AI strategy and emerging market expansion with analysts targeting $82 Verizon provides the highest yield at 6.6% [...] The post Best Dividend Stocks for Long-Term Investors – December 2025 appeared first on CoinCentral.

Best Dividend Stocks for Long-Term Investors – December 2025

2025/12/07 22:45

TLDR

  • Johnson & Johnson leads with a 3.0% yield and 62 consecutive years of dividend increases, trading at $206 with strong analyst support targeting $227
  • Coca-Cola offers a 2.9% yield with 63 years of dividend growth, backed by AI strategy and emerging market expansion with analysts targeting $82
  • Verizon provides the highest yield at 6.6% with 18 years of raises, trading at $41 as 5G rollout continues with $48.50 price target
  • Merck delivers 3.2% yield after a 41% six-month surge to $100, driven by Keytruda’s $25 billion in sales and strong HIV pipeline
  • Realty Income and Chevron round out the list with 5.0% monthly dividends and 4.2% yield respectively, offering diversification in real estate and energy

As December 2025 closes, investors are looking at dividend-paying stocks as markets react to Federal Reserve rate signals and global tensions. These six companies across healthcare, consumer staples, telecom, energy, and real estate offer yields averaging 4% with long histories of dividend growth.

The selections represent decades of consistent payments. Each company operates in different sectors to provide portfolio diversification.

Johnson & Johnson (JNJ): Healthcare Leader

Johnson & Johnson yields 3.0% with 62 consecutive years of dividend increases. The stock trades around $206, up 14% year-to-date.


JNJ Stock Card
Johnson & Johnson, JNJ

The company’s oncology products including Keytruda-related treatments drive current growth. Its medical device division adds revenue stability.

Fifteen analysts rate the stock a “Buy” with an average price target of $198. Guggenheim analyst Vamil Divan recently raised his target to $227.

Barclays maintains an “Equal-Weight” rating at $197. The firm projects earnings per share of $10.86 in 2025.

Coca-Cola (KO): Global Beverage Giant

Coca-Cola delivers a 2.9% yield backed by 63 years of dividend growth. The stock trades near $73 with gains from emerging markets.


KO Stock Card
The Coca-Cola Company, KO

Thirteen analysts give the stock a “Strong Buy” rating. The average price target sits at $78, representing a 7% potential increase.

UBS holds an $82 target following discussions about the company’s AI strategy. Seeking Alpha analysts note potential for cash recovery and dividend expansion.

Bank of America set an $80 price target. The firm points to a 25% increase in net income.

Verizon (VZ): Telecom Income Provider

Verizon offers the highest yield among the six at 6.6%. The stock trades around $41 with 18 years of dividend raises.


VZ Stock Card
Verizon Communications Inc., VZ

The company continues its 5G network expansion. Twelve analysts rate it a “Buy” with a $48.50 average target representing 18% upside.

Scotiabank maintains a “Sector Perform” rating at $50.50. The firm cites subscriber additions as a positive factor.

BNP Paribas Exane notes limited near-term growth drivers. Mizuho holds a “Hold” rating at $45 while highlighting free cash flow coverage.

Merck (MRK): Pharmaceutical Innovator

Merck provides a 3.2% yield with Keytruda generating over $25 billion in annual sales. The stock trades near $100 after climbing 41% over six months.

Thirteen analysts rate it a “Buy” with a $107 average target. J.P. Morgan set a $120 price target based on HIV pipeline developments.

Goldman Sachs also raised its target to $120. The upgrade reflects improved valuation metrics.

Analysts highlight the company’s revenue mix and profit margins. Patent expirations present future challenges offset by research investments.

Realty Income (O): Monthly Dividend REIT

Realty Income yields 5.0% with monthly dividend payments. The stock trades around $59 with a portfolio of 15,500 properties.

Thirteen analysts give it a “Hold” rating with a $62 target. Barclays set a $64 price target noting $6 billion in planned 2025 investments.

Wall Street Zen issued a “Sell” rating citing high valuation. Seeking Alpha points to the company’s A-rated balance sheet supporting dividend payments.

The real estate investment trust focuses on retail properties with long-term leases. Its portfolio design aims to withstand e-commerce pressure.

Chevron (CVX): Energy Producer

Chevron yields 4.2% at approximately $152 per share. The company operates major assets in the Permian Basin.

Seventeen analysts rate it a “Buy” with a $172 average target. HSBC set a $169 target highlighting share buyback programs.

Wells Fargo maintains a $196 target based on earnings beats. Morgan Stanley holds an “Overweight” rating at $177.

The company generates free cash flow to support dividend payments. Oil price movements create volatility in the stock price.

Summary

JNJ leads this pack for defensive prowess, but all six blend yield and growth for a fortified 2026 portfolio. With analyst thumbs up dominating, reinvest dividends and weather storms—your future self will thank you.

The post Best Dividend Stocks for Long-Term Investors – December 2025 appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.